Guolian Group signed a 10 billion fund and undertook a series of activities at the 2023 the Taihu Lake Bay Life and Health Future Conference
At the opening ceremony of the conference held on the morning of May 18th, Xicheng Venture Capital signed a 10 billion yuan contract with Guocheng Venture Capital Fund and Xintou Group for Guocheng Venture Capital Biotechnology (Wuxi) Fund; Xichuang Venture Capital has signed a $100 million contract with Yishike and Shengke to establish the Xichuang Yishike QFLP Biomedical Fund and Global Innovation Center.
The establishment of the National Venture Capital Biotechnology (Wuxi) Fund will be conducive to the further integration of state-owned capital and local resources. Through cooperation, both parties will jointly invest in high-quality projects in the biotechnology field, enhance the competitiveness of Wuxi's local biological industry cluster, and accelerate the construction of a regional collaborative innovation system in the the Taihu Lake Bay Science and Technology Innovation Belt. Wuxi Venture Capital, together with Singapore's leading life science tool company ESCO Yishike and Wuxi High tech Zone, set up the Wuxi Yishike QFLP Biomedical Fund, which will take full advantage of the special geographical position of ESCO Yishike in the "the Belt and Road", bring more cutting-edge innovative technology enterprises to Wuxi, and also help more local enterprises in Wuxi "go global".
On the afternoon of May 18th, the CICC Investment and Financing Forum, jointly organized by CICC and Guolian Group, was successfully held. This forum has continued to create a high-quality dialogue and exchange platform for the industry and investment sectors, promoting the exploration of new models and paths for development, helping industries, technology, and capital achieve higher levels of circulation and deeper integration, and contributing to the comprehensive construction of a new system for innovation, excellence, and sustainable development of Wuxi's biopharmaceutical industry.
On the afternoon of the same day, the Biomedical Fund Cooperation and Exchange Conference, jointly organized by Wuxi Science and Technology Bureau, Wuxi Local Financial Supervision and Administration Bureau, and Wuxi Innovation Investment Group Co., Ltd., was successfully held under the theme of "Guiding Unity and Promoting Symbiosis". This conference invites representatives of central enterprise funds, provincial and municipal level government industry fund managers, heads of leading domestic private equity fund management companies, and representatives of leading pharmaceutical industry enterprises through face-to-face communication and collision to jointly provide suggestions and strategies for improving the innovation and entrepreneurship ecology of Wuxi's biopharmaceutical industry, explore new paths for industry finance integration, and attract industries.
On May 19th, the conference on the pharmaceutical innovation industry chain ecosystem attracted active participation from numerous innovative pharmaceutical and medical device companies. The attending experts, guests, and representatives of enterprises expressed forward-looking, leading, and pioneering insights, gathering wisdom and strength for the high-quality development of Wuxi's biopharmaceutical industry.
